Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on TradePub.com for readers like you. LEARN MORE
Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor- Agnostic Era

Request Your Free White Paper Now:

"Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor- Agnostic Era"

Download this whitepaper to learn more.

As precision oncology transitions towards a targeted pan-tumor approach, comprehending prevalence rates and testing patterns becomes crucial for commercial success and adoption. Tumor-agnostic clinical trials might not completely grasp the clinical implications of treatment and efficacy due to patient diversity, underscoring the importance of real-world data to glean insights across various patient subgroups. With the innovative approach of targeting RET-rearranged tumors, we investigated the current landscape of RET testing to uncover both challenges and opportunities associated with this new pan-tumor indication. In this white paper, you will discover:

  • The RET testing modality landscape from 2017-2023
  • RET fusion status across 18 different tumor types from 2017-2023

The power of linking detailed genomic data to medical claims to enhance outcomes measures in specific patient-populations.


Offered Free by: NeoGenomics
See All Resources from: NeoGenomics

Recommended for Professionals Like You: